Feed APM
AP

Aptorum Group Limited

APM · NASDAQ

$8.26 -12.13% (-$1.14)
Analiză

Un raport AI despre afacere, finanțe, evaluare, sentiment, știri și riscuri - scris în câteva minute.

Piotroski F-Score Weak
2/9
Valuation
-
N/A
P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A
EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
-
N/A
ROIC N/A
ROE N/A
ROA N/A
Debt
-
N/A
Debt/Equity N/A
Current ratio N/A
Int. coverage N/A
Stability
0 /100
Unstable
Beta 0.17x
Rev. volatility N/A
EPS volatility N/A

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre APM
Online

Despre companie

Aptorum Group Limited (APM) is a global biotechnology company focused on the development of new drug candidates for the treatment of various diseases. Their research targets the treatment of infectious diseases, neurological and gastrointestinal disorders, oncological diseases, and other serious health conditions. Aptorum Group focuses on innovative therapeutic approaches, including the use of AI and bioinformatics technologies to discover new drug targets and therapies. The company is also active in the development of herbal-based medicines and traditional healing practices. Their aim is to bring innovative and effective therapeutic approaches to improve the health of patients worldwide. Aptorum Group Limited (APM) shares could be suitable for investors seeking investments in biotechnology companies with potential for innovative therapeutic development and global growth.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Ian Huen

Employees

2

Headquarters

Princeton

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.